Qiagen received 510(k) clearance for the QIAstat-Dx Rise Syndromic Testing System, an automated platform capable of processing up to 160 samples per day. The system allows automated cartridge loading, priority handling of urgent samples, and supports syndromic testing panels to improve diagnostic efficiency. This regulatory milestone enhances clinical laboratories’ ability to rapidly diagnose infectious diseases, particularly in high-demand settings, enabling improved patient management and outbreak response.